Experienced in Isolated ACTH Deficiency

Sandrine Aspeslagh

Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
Experienced in Isolated ACTH Deficiency
Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Sandrine Aspeslagh practices in Brussels, Belgium. Ms. Aspeslagh is rated as an Experienced expert by MediFind in the treatment of Isolated ACTH Deficiency. Her top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Isolated ACTH Deficiency, Tissue Biopsy, and Kidney Transplant.

Her clinical research consists of co-authoring 88 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Isolated ACTH Deficiency.

Gender
Female

Locations

Universitair Ziekenhuis Brussel
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2024
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Enrollment Status: Terminated
Publish Date: June 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

88 Total Publications

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
Journal: Acta oncologica (Stockholm, Sweden)
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aspeslagh's expertise for a condition
ConditionClose
        View All 25 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile